PRAVASTATIN SODIUM

Search structure


Trade Names:	PRAVACHOL PRAVASTATIN SODIUM
Synonyms:	CS-514 Dehypotin protect Elisor Eptastatin sodium Lipemol Liplat Lipostat NSC-759253 Pravachol Pravastatin sodium SQ-31,000 SQ-31000
Status:	Approved (1991)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	3M8608UQ61
Parent Compound:	PRAVASTATIN

Structure


InChI Key	VWBQYTRBTXKKOG-IYNICTALSA-M
Smile	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+]
InChI	InChI=1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H35NaO7
Molecular Weight	446.52
AlogP	2.44
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	10.0
Polar Surface Area	124.29
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	30.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	HMG-CoA reductase inhibitor	DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Oxidoreductase	-	4-40	-	-	28-48
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	100

Metabolites

visNetwork

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Ischemic Stroke	3	D000083242	ClinicalTrials
Diabetes Mellitus, Type 1	3	D003922	ClinicalTrials
Hyperlipidemia, Familial Combined	3	D006950	ClinicalTrials
Lipodystrophy	3	D008060	ClinicalTrials
Liver Neoplasms	3	D008113	ClinicalTrials
Lung Neoplasms	3	D008175	ClinicalTrials
HIV Infections	2	D015658	ClinicalTrials
HIV Infections	2	D015658	ClinicalTrials
Leukemia	2	D007938	ClinicalTrials

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Mixture

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Musculoskeletal and connective tissue disorders	15.11
General disorders and administration site conditions	10.39
Nervous system disorders	10.38
Gastrointestinal disorders	6.9
Skin and subcutaneous tissue disorders	6.74
Respiratory, thoracic and mediastinal disorders	5.82
Injury, poisoning and procedural complications	5.69
Cardiac disorders	4.97
Investigations	4.95
Vascular disorders	4.95
Psychiatric disorders	4.65
Immune system disorders	3.35
Metabolism and nutrition disorders	2.62
Renal and urinary disorders	2.02

Cross References

Resources	Reference
ChEBI	8361
ChEMBL	CHEMBL690
EPA CompTox	DTXSID6047525
FDA SRS	3M8608UQ61
KEGG	D00893
PubChem	16759173
SureChEMBL	SCHEMBL3013
ZINC	ZINC03798763

CONTENTS